Molecular pharmacology

The compound EU1794-4 lowers activity and calcium flow in specific brain NMDA receptors

Updated

Abstract

Coapplication of the negative allosteric modulator EU1794-4 with glutamate and glycine increases the fraction of time the NMDA channel is open by nearly 1.5-fold.

  • EU1794-4 reduces single-channel conductance by increasing access to several subconductance levels.
  • The overall effect of EU1794-4 is a reduction in the macroscopic current despite increased channel opening.
  • Negative modulation by EU1794-4 shows no voltage-dependence, indicating it does not act through a channel block mechanism.
  • EU1794-4 decreases calcium permeability relative to monovalent cations for GluN1/GluN2A receptors.
  • The properties of EU1794-4 suggest it could represent a new class of modulators that attenuate NMDA receptor function.

Simplified

Full Text

Full text is available at the source.

Funding

Competing interests

The opinions expressed in this paper are those of the authors and do not necessarily reflect the views of the funding agency. S.F.T. is a PI on research grants from Allergan, Biogen, and Janssen to Emory University; is a paid consultant for Janssen; is a member of the SAB for Sage Therapeutics, Eumentis, the GRIN2B Foundation, and the CureGRIN Foundation; is cofounder of NeurOp Inc. and Agrithera Inc.; and has received licensing fees and royalties from Emory. D.C.L. is on the Board of Directors of NeurOp Inc. S.F.T., B.K., H.Y., and D.C.L. are coinventors on Emory University–owned intellectual property that includes allosteric modulators of glutamate receptor function. H.Y. is a PI on research grant from Sage Therapeutics to Emory University.
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free